决定诺和诺德股价的关键：下一代减肥药数据下月公布

华尔街见闻11-18

半年跌超20%的诺和诺德，能否借助“下一代”减肥药物翻身？11月17日，《金融时报》报道，“减肥双雄”之一、丹麦制药公司诺和诺德准备在下个月发布其“下一代”减肥药物CagriSema的最终临床实验数据，诺和诺德预计实验结果将显示，CagriSema能在一年多的时间内减少使用者25%的体重。CagriSema结合了诺和诺德现有减肥药物Ozempic和Wegovy的活性成分——模拟肠道激素GLP-1的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484738696?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","is_english":false,"pubTime":"2024-11-18 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484738696","market":"us","top_or_hot":-1,"title":"决定诺和诺德股价的关键：下一代减肥药数据下月公布","media":"华尔街见闻","content":"<div>\n<p>半年跌超20%的诺和诺德，能否借助“下一代”减肥药物翻身？11月17日，《金融时报》报道，“减肥双雄”之一、丹麦制药公司诺和诺德准备在下个月发布其“下一代”减肥药物CagriSema的最终临床实验数据，诺和诺德预计实验结果将显示，CagriSema能在一年多的时间内减少使用者25%的体重。CagriSema结合了诺和诺德现有减肥药物Ozempic和Wegovy的活性成分——模拟肠道激素GLP-1的...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3734340\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>决定诺和诺德股价的关键：下一代减肥药数据下月公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n决定诺和诺德股价的关键：下一代减肥药数据下月公布\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 12:44 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3734340><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>半年跌超20%的诺和诺德，能否借助“下一代”减肥药物翻身？11月17日，《金融时报》报道，“减肥双雄”之一、丹麦制药公司诺和诺德准备在下个月发布其“下一代”减肥药物CagriSema的最终临床实验数据，诺和诺德预计实验结果将显示，CagriSema能在一年多的时间内减少使用者25%的体重。CagriSema结合了诺和诺德现有减肥药物Ozempic和Wegovy的活性成分——模拟肠道激素GLP-1的...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3734340\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://wallstreetcn.com/articles/3734340","article_id":"2484738696","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3734340","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2484738696","pubTimestamp":1731905092,"sourceInfo":{"source_id":"wallstreetcn_hot_news","name":"华尔街见闻"},"weMediaInfo":null,"summary":"诺和诺德将在下个月发布其“下一代”减肥药物CagriSema的最终临床实验数据，预计CagriSema能在一年多的时间内减少使用者25%的体重，有望占据GLP-1类减重药物的领先地位。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德"},"translate_title":"The key to determining Novo Nordisk's stock price: Next-generation diet pill data released next month","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/16532c353308ca418b5e12ed2fdfd946","symbols_score_info":{"NVO":1},"content_text":"半年跌超20%的诺和诺德，能否借助“下一代”减肥药物翻身？11月17日，《金融时报》报道，“减肥双雄”之一、丹麦制药公司诺和诺德准备在下个月发布其“下一代”减肥药物CagriSema的最终临床实验数据，诺和诺德预计实验结果将显示，CagriSema能在一年多的时间内减少使用者25%的体重。CagriSema结合了诺和诺德现有减肥药物Ozempic和Wegovy的活性成分——模拟肠道激素GLP-1的semaglutide，以及基于胰腺激素胰岛淀粉样肽的化合物cagrilintide，每周注射一次进行治疗。相比诺和诺德现有的重磅治疗药物Wegovy（最多减重16%）和另一“减肥双雄”礼来的竞争药物Mounjaro（最多减重22.5%），CagriSema的减重效果更为显著，有望占据GLP-1类减重药物的领先地位。诺和诺德CEO Lars Fruergaard Jørgensen在公司发布三季度财报时表示：“CagriSema对我们来说非常重要，这是一款下一代产品，具有成为行业标杆的潜力。”至关重要的CagriSema近期，诺和诺德的股价未能与其最大竞争对手礼来的股价保持同步增长。过去6个月，诺和诺德股价跌超22%，目前报101.74美元/股。投资者对诺和诺德满足产品需求的能力产生了疑虑，并且，9月诺和诺德一款减肥药物的实验结果不佳。不过，Jørgensen指出，Wegovy近期已经从美国短缺清单上移除了，这表明，诺和诺德有能力满足市场需求，公司股价波动表明，“围绕肥胖治疗的炒作可能引发了一些对公司业务状况的误解”。如果CagriSema的实验数据未能达到预期，投资者可能会重新考虑诺和诺德在减肥领域的领导地位。巴克莱分析师Emily Field表示：“这是整个年度制药行业最重要的数据点，要么诺和诺德找到通向下一个十年的道路，要么就找不到。”值得注意的是，“下一代”减肥药物不仅对诺和诺德意义重大，也对整个行业也至关重要。CagriSema的结果将是首个有关胰岛素类药物的高级数据，目前，许多制药公司正在开发基于胰岛素的治疗方法，CagriSema的成功可能会增强投资者对一些制药公司的信心。北欧联合银行分析师Michael Novod表示：“这是诺和诺德展现创新能力的关键时刻，也是为其他药物设立新目标的时刻。”","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484738696"}